LIVER FASt ™
Blood-based liver evaluation test that uses 10 biomarkers and advanced technology to determine the condition of the liver
What is LIVERFASt™?
LIVERFASt™ provides a score from 0.00 to 1.00 and its estimated grade or stage, similar to the histopathological scoring of the liver (based on the liver biopsy classification).
Alpha-2-Macroglobulin
Haptoglobin
Apolipoprotein A1
Total Bilirubin
GGT
ALT
AST
Fasting Glucose
Tryglycerides
Total Cholesterol
How it Works
Simple and easy-to-do
Physician prescribes LIVERFASt™
Lab analyzes 10 biomarkers from 1 blood draw
Biomarker values plus age, height, weight, gender are entered into the platform
LIVERFASt™ results are available immediately
Download Test Requisition Form (US only)
What does LIVERFASt™ Measure?
LIVERFASt™ takes inputs from 10 biomarkers and patient anthropometrics to generate a score from 0.00 to 1.00 that corresponds to the histopathological staging of a liver biopsy.
Fibrosis
STAGE
| Stage | Interpretation |
|---|---|
| FO | No fibrosis |
| F1 | Mild fibrosis |
| F2 | Advanced fibrosis |
| F3 | Significant fibrosis |
| F4 | Severe fibrosis/cirrhosis |
Activity
STAGE
| Stage | Interpretation |
|---|---|
| aO | No activity |
| a1 | Mild activity |
| a2 | Moderate activity |
| a3 | Marked activity |
| a4 | Severe activity |
Steatosis
STAGE
| Stage | Interpretation |
|---|---|
| sO | No steatosis (<5%) |
| s1 | Mild steatosis(5-33%) |
| s2 | Moderate steatosis(34-66%) |
| s3 | Marked steatosis (≥ 67%) |
Clinical Validation
LIVERFASt, the best screening tool that also stages liver fibrosis, steatosis & inflammatory activity. LIVERFASt predicts biopsy results, ALT, and AST do not.
LIVIRFASt has high clinical performance for Fibrosis & Activity
LIVIRFASt Activity Test performance
MASLD population(n=223)
- ADRDC (95%CI): 0.79 (0.71-0.85)
- Specificity: 0.85
- Sensitivity: 0.59
- Negative Predictive Value: 0.65
- Positive Predictive Value: 0.85
LIVIRFASt Fibrosis Test performance
MASLD population(n=223)
- ADRDC (95%CI): 0.867 (0.807-0.910)
- Specificity: 0.85
- Sensitivity: 0.75
- Negative Predictive Value: 0.88
- Positive Predictive Value: 0.71
The concordance for cirrhosis with Liver Biopsy (n=452)
- LIVERFASt: 67/95 (71%)
- LSM: 51/95 (54%)
- FIB-4: 45/95 (47%)
Integration and Usability
LIVERFASt™ seamlessly integrates into any clinical or healthcare setting, supporting your clinical paths and processes.
Easily Run on any Browser
Screening of all at-risk patients
Interested in Partnering with Us?
Contact our sales representative to inquire more about LIVERFASt™ and how it can help you and your patients improve their liver health.